Codexis Inc CDXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Codexis to Report Third Quarter 2026 Financial Results on November 12
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
Codexis to Participate in Cantor Global Healthcare Conference 2026
Codexis Reports Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $1.02
- Day Range
- $1.03–1.10
- 52-Week Range
- $0.96–2.98
- Bid/Ask
- $1.07 / $1.09
- Shares Outstanding
- 110.06M
- Market Cap
- $118.27M
- Volume/Avg
- 400,316 / 927,577
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- < 0.01%
Company Profile
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 146
- Website
- https://www.codexis.com
Valuation
Metric | CDXS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.99 |
Price/Sales | 1.26 |
Price/Cash Flow | — |
Price/Earnings
CDXS
Financial Strength
Metric | CDXS |
|---|---|
Quick Ratio | 2.83 |
Current Ratio | 3.06 |
Interest Coverage | −5.05 |
Quick Ratio
CDXS
Profitability
Metric | CDXS |
|---|---|
Return on Assets (Normalized) | −16.63% |
Return on Equity (Normalized) | −49.64% |
Return on Invested Capital (Normalized) | −16.95% |
Return on Assets
CDXS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|>>q&%V< | LOCK|^y%$& | $139B | |||
| Moderna Inc MRNA | LOCK|%%&Dc$ | LOCK|>g | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|my#>%<l | LOCK|w@WD | $94B | |||
| argenx SE ADR ARGX | LOCK|dWs^#d | LOCK|G!h | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#SK#$>d | LOCK|%@N | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>QB#NSXY | LOCK|?BK@ | $30B | |||
| Incyte Corp INCY | LOCK|#$D@cP | LOCK|fH | $24B | |||
| BioNTech SE ADR BNTX | LOCK|@%nGjw> | LOCK|PF | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^H<d%z< | LOCK|Dc!y | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|r^&ZR%F | LOCK|C@K | $15B |
United States